Idera Pharmaceuticals, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 1989-01-01

Employees: 51

Market Cap: -

Website: http://www.aceragen.com

Clinical Trials

Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)

Phase 2

Active, not recruiting

Conditions: Solid Tumor

Interventions: Drug: Tilsotolimod
Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2019-03-06

Last Posted Date: 2022-02-17

Lead Sponsor: Idera Pharmaceuticals, Inc.

Target Recruit Count: 30

Registration Number: NCT03865082

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of Southern California/ Hoag Hospital Presbyterian, Newport Beach, California, United States
🇺🇸
Banner University Medical Center Tucson Campus, Tucson, Arizona, United States

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

Phase 3

Terminated

Conditions: Metastatic Melanoma

Interventions: Drug: Tilsotolimod with Ipilimumab
Drug: Ipilimumab

First Posted Date: 2018-02-26

Last Posted Date: 2022-11-08

Lead Sponsor: Idera Pharmaceuticals, Inc.

Target Recruit Count: 481

Registration Number: NCT03445533

Locations: 🇩🇪
Universitatsklinikum Regensburg, Regensburg, Germany
🇫🇷
CHU Amiens Picardie - Hopital Sud, Amiens, France
🇺🇸
Sutter Health Sacramento, Sacramento, California, United States

and more 77 locations

A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors

Phase 1

Completed

Conditions: Refractory Solid Tumors
Melanoma

Interventions: Drug: IMO-2125

First Posted Date: 2017-02-14

Last Posted Date: 2020-02-11

Lead Sponsor: Idera Pharmaceuticals, Inc.

Target Recruit Count: 54

Registration Number: NCT03052205

Locations: 🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
Scottsdale Healthcare Hospitals DBA Honor Health, Scottsdale, Arizona, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

and more 9 locations

A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Metastatic Melanoma

Interventions: Drug: IMO-2125
Drug: Ipilimumab

First Posted Date: 2016-01-01

Last Posted Date: 2022-08-03

Lead Sponsor: Idera Pharmaceuticals, Inc.

Target Recruit Count: 53

Registration Number: NCT02644967

Locations: 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸
University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸
Icahn School Of Medicine at Mount Sinai, New York, New York, United States

and more 7 locations

Trial of IMO-8400 in Adult Patients With Dermatomyositis

Phase 2

Completed

Conditions: Dermatomyositis

Interventions: Drug: IMO-8400 Dose Group 1
Drug: Placebo
Drug: IMO-8400 Dose Group 2

First Posted Date: 2015-11-24

Last Posted Date: 2019-10-10

Lead Sponsor: Idera Pharmaceuticals, Inc.

Target Recruit Count: 30

Registration Number: NCT02612857

Locations: 🇺🇸
University of California, Irvine, Irvine, California, United States
🇺🇸
Northwell Health, Great Neck, New York, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States

and more 17 locations

Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401

Phase 1

Completed

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly

First Posted Date: 2015-02-16

Last Posted Date: 2018-01-09

Lead Sponsor: Idera Pharmaceuticals, Inc.

Target Recruit Count: 5

Registration Number: NCT02363439

Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation

Phase 1

Completed

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: IMO-8400

First Posted Date: 2014-09-30

Last Posted Date: 2017-12-12

Lead Sponsor: Idera Pharmaceuticals, Inc.

Target Recruit Count: 6

Registration Number: NCT02252146

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Cancer Care Specialists of Illinois, Decatur, Illinois, United States
🇺🇸
Horizon Bio Advance, Lafayette, Indiana, United States

and more 9 locations

Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

Phase 1

Terminated

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: IMO-8400

First Posted Date: 2014-03-20

Last Posted Date: 2019-09-10

Lead Sponsor: Idera Pharmaceuticals, Inc.

Target Recruit Count: 31

Registration Number: NCT02092909

Locations: 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸
Emory Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 7 locations

A 12-week Dose-Ranging Trial in Patients With Moderate to Severe Plaque Psoriasis

Phase 2

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Saline Placebo
Drug: IMO-8400 Regimen 4
Drug: IMO-8400 Regimen 3
Drug: IMO-8400 Regimen 1
Drug: IMO-8400 Regimen 2

First Posted Date: 2013-07-15

Last Posted Date: 2022-04-07

Lead Sponsor: Idera Pharmaceuticals, Inc.

Target Recruit Count: 46

Registration Number: NCT01899729

Locations: 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands

Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis

Phase 2

Completed

Conditions: Actively Extending Plaque Psoriasis
Moderate to Severe Plaque Psoriasis

Interventions: Drug: Saline for Injection
Drug: IMO-3100 at 0.16 mg/kg
Drug: IMO-3100 at 0.32 mg/kg

First Posted Date: 2012-06-19

Last Posted Date: 2018-01-09

Lead Sponsor: Idera Pharmaceuticals, Inc.

Target Recruit Count: 44

Registration Number: NCT01622348

Locations: 🇺🇸
Atlanta Dermatology, Vein & Research Center, PC, Alpharetta, Georgia, United States
🇺🇸
DermResearch PLLC, Louisville, Kentucky, United States
🇺🇸
J & S Studies, College Station, Texas, United States

and more 10 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy